Endoscopy in Inflammatory Bowel Disease: Western Perspectives-North America

2017 ◽  
pp. 267-274
Author(s):  
Hans Herfarth ◽  
Todd Baron
Keyword(s):  
Inflammatory Bowel Disease ◽  
North America ◽  
Bowel Disease ◽  
Inflammatory Bowel

scholarly journals The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis

2022 ◽  
Author(s):  
Gilaad G Kaplan ◽  
Fox E Underwood ◽  
Stephanie Coward ◽  
Manasi Agrawal ◽  
Ryan C Ungaro ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Latin America ◽  
North America ◽  
Trend Analysis ◽  
Bowel Disease ◽  
Temporal Trend ◽  
Temporal Trends ◽  
International Registry ◽  
Inflammatory Bowel

Abstract Background Cases of coronavirus disease 2019 (COVID-19) have emerged in discrete waves. We explored temporal trends in the reporting of COVID-19 in inflammatory bowel disease (IBD) patients. Methods The Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is an international registry of IBD patients diagnosed with COVID-19. The average percent changes (APCs) were calculated in weekly reported cases of COVID-19 during the periods of March 22 to September 12, September 13 to December 12, 2020, and December 13 to July 31, 2021. Results Across 73 countries, 6404 cases of COVID-19 were reported in IBD patients. COVID-19 reporting decreased globally by 4.2% per week (95% CI, −5.3% to −3.0%) from March 22 to September 12, 2020, then climbed by 10.2% per week (95% CI, 8.1%-12.3%) from September 13 to December 12, 2020, and then declined by 6.3% per week (95% CI, −7.8% to −4.7%). In the fall of 2020, weekly reporting climbed in North America (APC, 11.3%; 95% CI, 8.8-13.8) and Europe (APC, 17.7%; 95% CI, 12.1%-23.5%), whereas reporting was stable in Asia (APC, −8.1%; 95% CI, −15.6-0.1). From December 13, 2020, to July 31, 2021, reporting of COVID-19 in those with IBD declined in North America (APC, −8.5%; 95% CI, −10.2 to −6.7) and Europe (APC, −5.4%; 95% CI, −7.2 to −3.6) and was stable in Latin America (APC, −1.5%; 95% CI, −3.5% to 0.6%). Conclusions Temporal trends in reporting of COVID-19 in those with IBD are consistent with the epidemiological patterns COVID-19 globally.

Underutilization of Bowel Ultrasound in North America in Children with Inflammatory Bowel Disease

2019 ◽  
Vol 38 (5) ◽  
pp. 390-397
Author(s):  
Heidi E. Gamboa ◽  
Zarela Molle-Rios ◽  
Sudha A. Anupindi
Keyword(s):  
Inflammatory Bowel Disease ◽  
North America ◽  
Bowel Disease ◽  
Bulletin Board ◽  
Observer Variability ◽  
The North ◽  
Widespread Adoption ◽  
Inter Observer Variability ◽  
Inflammatory Bowel ◽  
Bowel Ultrasound

Background: Inflammatory bowel disease (IBD) is a chronic relapsing disease that requires evaluation using multiple objective tools. In Europe, bowel ultrasound (US) is a widely accepted modality used for the management of patients with IBD; however, its use in North America has only recently emerged as a potential technique. Objectives: Our goal was to identify current practice patterns of pediatric gastroenterologists and radiologists using bowel US in patients with IBD and highlight perceived limitations to the widespread adoption of this modality in North America. Methods: A 14-question survey was e-mailed to the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition internet bulletin board composed of 3,058 subscribers from 51 countries; the Society of Pediatric Radiology listserv composed of 1,917 subscribers worldwide; and the Society of Chairs of Radiology at Children’s Hospitals listserv. Descriptive summary statistics was used. Results: In North America, about one-quarter of gastroenterology and radiology participants reported using bowel US for IBD; over 3-fourths expressed an interest in using US more often. Bowel US was performed more frequently for Crohn’s disease. Both groups agreed the main limitation to using bowel US was concern for inter-observer variability and operator-dependent factors; radiologists reported that other modalities are more effective to assess IBD, whereas gastroenterologists reported unfamiliarity with bowel US indications and techniques. Conclusions: Our data show there is significant interest among both radiologists and gastroenterologists in using bowel US. However, lack of education, insufficient training, and perceived high inter-observer variability among US technologists are limitations preventing the widespread adoption of US for IBD in North America.

scholarly journals P317 Societal cost-of-illness of Inflammatory Bowel Disease has rapidly increased over the years and differs between continents: A systematic review

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S343-S344
Author(s):  
R Van Linschoten ◽  
E Visser ◽  
C Niehot ◽  
J van der Woude ◽  
J Hazelzet ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
North America ◽  
Cost Of Illness ◽  
Bowel Disease ◽  
Healthcare Costs ◽  
Cost Drivers ◽  
Medication Costs ◽  
Inflammatory Bowel ◽  
The Cost

Abstract Background With increasing incidence of Inflammatory Bowel Disease (IBD) in developing countries and increasing prescription rates for biologics globally, knowledge on the cost burden of IBD and cost drivers is essential for health policy makers worldwide. We conducted a systematic review to determine cost-of-illness of IBD and assess time trends and geographical differences. Methods A systematic review of population-based studies that estimated cost-of-illness of IBD and were published in Embase, Medline, Web of Science and Google Scholar. Studies on interventions and those reporting costs for a subset of patients defined by phenotype or treatment were excluded, as these do not give a representative estimate of the cost-of-illness of IBD. Only studies published in English were included. Methodology of all included studies was assessed and costs were adjusted to 2018 US dollars. Results In total, 4,837 unique studies were screened on title and abstract and 4,730 excluded. After full-text screening, 64 of the remaining 107 studies were included in the systematic review. The study methodologies differed considerably, with large differences in perspective, valuation method and source population. Mean annual healthcare costs for prevalent Crohn′s disease (CD) cases in the last 10 years were in Asia $4,463; Europe $12,396 and North America $17,508. Costs for prevalent ulcerative colitis (UC) patients in the same period were $1,654, $7,206 and $13,569 respectively. For CD, the cost drivers moved from inpatient (61% of total costs) in 1995 to medication costs (77%) in 2016. Similar trends were identified for UC (1998: 50% and 36% versus 2016: 9%, and 82% for inpatient and medication costs, respectively). This cost trend is primarily attributable to an increase in medication costs in all four geographical areas, while in- and outpatient costs were relatively stable during the same time period. The annual costs of absenteeism and presenteeism per prevalent case of CD were $5,638 in Asia and $6,485 in Europe. For UC these costs were $4,828 and $6,414 respectively. Annual costs of absenteeism and presenteeism in North America were $20,074 per patient for a combined cohort of UC and CD patients. Conclusion Per patient costs for IBD are increasing worldwide, with highest costs in North America and lowest in Asia. This is primarily due to an increase in medication costs. Productivity costs are substantial and might even exceed healthcare costs. Biologic therapy was expected to decrease inpatient costs by reducing hospitalisations and surgery, but this does not appear to be the case. Continuing growth of these costs can lead to an intolerable burden on healthcare systems worldwide.

Epidemiology of Inflammatory Bowel Disease

2015 ◽  
Author(s):  
Edward L. Barnes ◽  
Robert Burakoff
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Disease ◽  
North America ◽  
Bowel Disease ◽  
Geographic Location ◽  
The United States ◽  
Underlying Disease ◽  
Global Scale ◽  
Individual Level ◽  
Inflammatory Bowel

Inflammatory bowel disease (IBD) comprises chronic disorders characterized by inflammation of the gastrointestinal tract. The two major identified subtypes of IBD are ulcerative colitis (UC) and Crohn disease (CD), and over many years, each can demonstrate periods of recurrence and remission. Although the presentation and clinical patterns of UC and CD have been well studied, many questions remain regarding the underlying disease pathogenesis. On an individual level, the development of clinically active IBD appears to occur on account of a complex set of interactions of distinct risk factors, including genetic predisposition, environmental exposures, and geographic location. On a global scale, the highest rates of IBD are found in Europe and North America, with worldwide prevalence of UC and CD increasing. Figures show the prevalence of UC and CD in the United States, stratified by region. Tables show the prevalence of IBD in North America as identified by various studies and environmental risk factors for inflammatory bowel disease. This review contains 2 highly rendered figures, 2 tables, and 134 references. 

scholarly journals A25 THE RISING GLOBAL INCIDENCE OF PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW OF POPULATION-BASED STUDIES

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 144-145
Author(s):  
E Kuenzig ◽  
S G Fung ◽  
L Marderfeld ◽  
J W Mak ◽  
G G Kaplan ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Saudi Arabia ◽  
North America ◽  
Bowel Disease ◽  
Population Based ◽  
Northern Europe ◽  
Global Trends ◽  
Inflammatory Bowel ◽  
Pediatric Onset ◽  
Pediatric Ibd

Abstract Background The incidence of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is increasing internationally, particularly in developing nations where rates were historically low. Previous reports of the incidence and prevalence of pediatric-onset IBD have identified a paucity of population-based studies. Aims We reviewed the global trends in incidence of pediatric IBD using evidence from population-based studies. Methods (PROSPERO CRD42019125193) We systematically reviewed studies indexed in MEDLINE, EMBASE, Airiti Library, and SciELO from 01/2010-02/2020 to identify population-based studies reporting the incidence of pediatric-onset IBD, CD, and UC. Included studies combined childhood and adolescent-onset IBD (onset <21y). Changes in incidence since 2000 were plotted by continent, with data from 2000–09 provided by our previous systematic review1. To depict trends, multiple times points reported in single studies were connected on graphs. When incidence was reported as an aggregated estimate over a range of years, data was plotted using the midpoint of the interval. Results Of 8096 abstracts screened, 74 studies described the incidence of IBD, CD, or UC in 33 countries (Figure panel A). The incidence of pediatric-onset IBD is highest in Northern Europe and North America, and lowest in Southern Europe, Asia, and the Middle East. This geographical distribution is similar in UC, while incidence of pediatric-onset CD is highest in North America and Northern Europe, followed by Australia. Trends in incidence over time, stratified by continent, are reported in Figure, panel B. Significantly increasing incidence of IBD, CD, and/or UC was reported in China, Bahrain, Canada, New Zealand, Australia, Singapore, Saudi Arabia, and most European countries. Very Early Onset (VEO) IBD significantly increased in Canada, however Saudi Arabia reported decreasing incidence of VEO-CD but stable incidence of VEO-UC. Conclusions Conclusion: Incidence of pediatric-onset IBD are highest in Northern Europe and North American and are increasing globally. There remains a paucity of studies from many parts of the world on the incidence pediatric IBD. Further research is needed to understand the pathogenesis of the rising incidence of pediatric IBD, including work to understand the genetic, environmental, immunological and microbiome alterations leading to the increasing rates in children. References: 1Benchimol, Fortinsky et al. Inflamm Bowel Dis 2011;17:423–39. Funding Agencies None

The Rising Burden of Inflammatory Bowel Disease in North America from 2015 to 2025: A Predictive Model

2015 ◽  
Vol 110 ◽  
pp. S829 ◽  
Author(s):  
Stephanie Coward ◽  
Fiona Clement ◽  
Tyler Williamson ◽  
Glen Hazlewood ◽  
Siew Ng ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
North America ◽  
Predictive Model ◽  
Bowel Disease ◽  
Inflammatory Bowel

scholarly journals Diet and Nutrition in IBD—Progress and Gaps

Nutrients ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1740
Author(s):  
Maitreyi Raman ◽  
Subrata Ghosh
Keyword(s):  
Inflammatory Bowel Disease ◽  
North America ◽  
Bowel Disease ◽  
Inflammatory Bowel

The incidence and prevalence of Inflammatory Bowel Disease (IBD) has rapidly increased worldwide and now is a global disease with some of the highest rates observed in North America [...]

Sign in / Sign up

Export Citation Format

Share Document